Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Bulbospinal Muscular Atrophy Drug Market Report. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


Bulbospinal Muscular Atrophy Drug Trends and Forecast

The future of the global bulbospinal muscular atrophy drug market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global bulbospinal muscular atrophy drug market is expected to grow with a CAGR of 5.2% from 2024 to 2030. The major drivers for this market are growing investments in rare disease drug development, increasing awareness & diagnosis of bulbospinal muscular atrophy, and rising advancements in genetic research leading to targeted therapies.
• Lucintel forecasts that leuprorelin is expected to witness the higher growth over the forecast period.
• Within this market, hospital is expected to witness the highest growth.
• North America is expected to witness the highest growth over the forecast period due to growing awareness among healthcare professionals in the region.

Bulbospinal Muscular Atrophy Drug Trends and Forecast

United States: BiotechPharma Inc. announced the initiation of phase III clinical trials for a novel BSMA drug targeting SMN2 gene expression.

Japan: Japanese pharmaceutical company Kyowa Kirin Co. introduced a BSMA drug with neuroprotective properties, aiming to improve motor function in affected patients.

China: Beijing Genomics Institute (BGI) initiated genome sequencing projects for BSMA patients, contributing to personalized medicine approaches.

Germany: BioTechGmbH initiated preclinical studies for a BSMA gene therapy using CRISPR-Cas9 technology, showcasing GermanyÄX%$%Xs leadership in genetic medicine research.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Bulbospinal Muscular Atrophy Drug by Segment

Bulbospinal Muscular Atrophy Drug by Segment

The study includes a forecast for the global bulbospinal muscular atrophy drug by type, application, and region.

Bulbospinal Muscular Atrophy Drug Market by Type [Shipment Analysis by Value from 2018 to 2030]:


• Leuprorelin
• Dutasteride
• Others

Bulbospinal Muscular Atrophy Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:


• Hospital
• Homecare
• Specialty Clinic
• Others

Bulbospinal Muscular Atrophy Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:


• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Bulbospinal Muscular Atrophy Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bulbospinal muscular atrophy drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bulbospinal muscular atrophy drug companies profiled in this report include-
• Novartis
• F. Hoffmann-La Roche
• Boehringer Ingelheim
• Pfizer
• Ionis Pharmaceuticals
• Cytokinetics
• Regeneron Pharmaceuticals
• Salarius Pharmaceuticals
• Leadiant Biosciences
• Abbott

Recent Development in the Bulbospinal Muscular Atrophy Drug Market

BiotechPharma Inc.: Initiated phase III clinical trials for a novel BSMA drug targeting SMN2 gene expression, marking a significant advancement in BSMA treatment options.

PharmaGenetics LLC: Disclosed plans for developing a gene therapy approach for BSMA treatment, showcasing advancements in genetic medicine and personalized therapies.

Kyowa Kirin Co.: Introduced a BSMA drug with neuroprotective properties, aiming to improve motor function in affected patients, addressing a critical need in BSMA management.

Takeda Pharmaceutical Company Limited: Collaborated with academic institutions for BSMA biomarker research, enhancing diagnostic accuracy and paving the way for personalized treatment strategies.

BioTechGmbH: Initiated preclinical studies for a BSMA gene therapy using CRISPR-Cas9 technology, showcasing GermanyÄX%$%Xs leadership in genetic medicine research and innovative therapies.

Features of the Global Bulbospinal Muscular Atrophy Drug Market

Market Size Estimates: Bulbospinal muscular atrophy drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Bulbospinal muscular atrophy drug market size by type, application, and region in terms of value ($B).
Regional Analysis: Bulbospinal muscular atrophy drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the bulbospinal muscular atrophy drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bulbospinal muscular atrophy drug market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for bulbospinal muscular atrophy drug market?
Answer: The global bulbospinal muscular atrophy drug market is expected to grow with a CAGR of 5.2% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the bulbospinal muscular atrophy drug market?
Answer: The major drivers for this market are growing investments in rare disease drug development, increasing awareness & diagnosis of bulbospinal muscular atrophy, and rising advancements in genetic research leading to targeted therapies.
Q3. What are the major segments for bulbospinal muscular atrophy drug market?
Answer: The future of the bulbospinal muscular atrophy drug market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.
Q4. Who are the key bulbospinal muscular atrophy drug market companies?
Answer: Some of the key bulbospinal muscular atrophy drug companies are as follows:
• Novartis
• F. Hoffmann-La Roche
• Boehringer Ingelheim
• Pfizer
• Ionis Pharmaceuticals
• Cytokinetics
• Regeneron Pharmaceuticals
• Salarius Pharmaceuticals
• Leadiant Biosciences
• Abbott
Q5. Which bulbospinal muscular atrophy drug market segment will be the largest in future?
Answer: Lucintel forecasts that leuprorelin is expected to witness the higher growth over the forecast period.
Q6. In bulbospinal muscular atrophy drug market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period due to growing awareness among healthcare professionals in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the bulbospinal muscular atrophy drug market by type (leuprorelin, dutasteride, and others), application (hospital, homecare, specialty clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

For any questions related to Bulbospinal Muscular Atrophy Drug Market, Bulbospinal Muscular Atrophy Drug Market Size, Bulbospinal Muscular Atrophy Drug Market Growth, Bulbospinal Muscular Atrophy Drug Market Analysis, Bulbospinal Muscular Atrophy Drug Market Report, Bulbospinal Muscular Atrophy Drug Market Share, Bulbospinal Muscular Atrophy Drug Market Trends, Bulbospinal Muscular Atrophy Drug Market Forecast, Bulbospinal Muscular Atrophy Drug Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents

1. Executive Summary
2. Global Bulbospinal Muscular Atrophy Drug Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Bulbospinal Muscular Atrophy Drug Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Bulbospinal Muscular Atrophy Drug Market by Type
3.3.1: Leuprorelin
3.3.2: Dutasteride
3.3.3: Others
3.4: Global Bulbospinal Muscular Atrophy Drug Market by Application
3.4.1: Hospital
3.4.2: Homecare
3.4.3: Specialty Clinic
3.4.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Bulbospinal Muscular Atrophy Drug Market by Region
4.2: North American Bulbospinal Muscular Atrophy Drug Market
4.2.1: North American Bulbospinal Muscular Atrophy Drug Market by Type: Leuprorelin, Dutasteride, and Others
4.2.2: North American Bulbospinal Muscular Atrophy Drug Market by Application: Hospital, Homecare, Specialty Clinic, and Others
4.3: European Bulbospinal Muscular Atrophy Drug Market
4.3.1: European Bulbospinal Muscular Atrophy Drug Market by Type: Leuprorelin, Dutasteride, and Others
4.3.2: European Bulbospinal Muscular Atrophy Drug Market by Application: Hospital, Homecare, Specialty Clinic, and Others
4.4: APAC Bulbospinal Muscular Atrophy Drug Market
4.4.1: APAC Bulbospinal Muscular Atrophy Drug Market by Type: Leuprorelin, Dutasteride, and Others
4.4.2: APAC Bulbospinal Muscular Atrophy Drug Market by Application: Hospital, Homecare, Specialty Clinic, and Others
4.5: ROW Bulbospinal Muscular Atrophy Drug Market
4.5.1: ROW Bulbospinal Muscular Atrophy Drug Market by Type: Leuprorelin, Dutasteride, and Others
4.5.2: ROW Bulbospinal Muscular Atrophy Drug Market by Application: Hospital, Homecare, Specialty Clinic, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Bulbospinal Muscular Atrophy Drug Market by Type
6.1.2: Growth Opportunities for the Global Bulbospinal Muscular Atrophy Drug Market by Application
6.1.3: Growth Opportunities for the Global Bulbospinal Muscular Atrophy Drug Market by Region
6.2: Emerging Trends in the Global Bulbospinal Muscular Atrophy Drug Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Bulbospinal Muscular Atrophy Drug Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bulbospinal Muscular Atrophy Drug Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Novartis
7.2: F. Hoffmann-La Roche
7.3: Boehringer Ingelheim
7.4: Pfizer
7.5: Ionis Pharmaceuticals
7.6: Cytokinetics
7.7: Regeneron Pharmaceuticals
7.8: Salarius Pharmaceuticals
7.9: Leadiant Biosciences
7.10: Abbott
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Bulbospinal Muscular Atrophy Drug Market Report: Trends, Forecast and Competitive Analysis to 2030 Full Report $ 4,850
A 150 Page Report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.